Both in Pharmaceuticals
Design Therapeutics vs Kura Oncology
Over the past year DSGN returned +70.4% and KURA returned −23.6%; their daily moves had a correlation of 0.30.
DSGN +70.4% KURA −23.6%Growth of $1, one year, split-adjusted
| Metric | DSGN | KURA |
|---|---|---|
| Price | $10.63 | $7.61 |
| Market cap | $665.2M | $677.0M |
| Today | +2.80% | −22.98% |
| 1 month | −11.2% | −27.7% |
| 6 months | −26.9% | −20.4% |
| Year to date | +13.3% | −26.8% |
| 1 year | +62.3% | −22.1% |
| Revenue growth (YoY) | — | +36.5% |
| Gross margin | — | 98.8% |
| Net margin | — | −327.3% |
| P/E (TTM) | — | — |
| Price / sales | — | 8.8× |
| Net cash | $207.4M | $509.2M |
| Dividend yield | — | — |
| Volatility (60d) | 55.4% | 76.9% |
| Short % of float | 21.8% | 18.3% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).